aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview

aTyr Pharma

12/03/2024 21:35

* aTyr Pharma Inc  LIFE.OQ   LIFE.O  is expected to show a
fall in
quarterly revenue when it reports  results on March 14 for the
period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
99.5% decrease in revenue to $52 thousand from $10.39 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for aTyr Pharma Inc is for a
loss
of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for aTyr Pharma
Inc
is $25.00​, above​ its last closing price of $1.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.22       -0.23      -0.20     Beat    11.5
 Jun. 30 2023  -0.28       -0.28      -0.22     Beat    21
 Mar. 31 2023  -0.40       -0.40      -0.29     Beat    27.2​
 Dec. 31 2022  -0.48       -0.48      -0.26     Beat    45.8
 ​​Sep.        -0.45       -0.46      -0.46     Met     0.4
 30 2022                                                
 Jun. 30 2022  -0.39       -0.38      -0.44     Missed  -15.2​
 Mar. 31 2022  -0.33       -0.33      -0.44     Missed  -32.7
 Dec. 31 2021              -0.28      -0.31     Missed  -9.4
 This summary was machine generated March 12 at 21:35 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)